A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.

Yuan-Di HalvorsenJohn P LockWenjiong ZhouFang ZhuMason W Freeman

Published in: Diabetes, obesity & metabolism (2019)

Bexagliflozin was non-inferior to sitagliptin and provided benefits over sitagliptin in FPG and body mass. Adverse event incidences in the two arms were similar.

Keyphrases

double blind
placebo controlled
clinical trial
phase ii
phase iii
open label
study protocol
emergency department
combination therapy